AstraZeneca’s R&D spend rises 5% YoY in 2026 despite trial setback
Resolves: AstraZeneca’s reported R&D expenses for the full fiscal year 2026 exceed the 2025 R&D expenses by at least 5% when reported in its 2026 annual or Q4 2026 earnings filings (or equivalent regulatory disclosures).
user-generated· earnings
AstraZeneca’s R&D spend rises 5% YoY in 2026 despite trial setback
Market overview
To maintain its pipeline premium, AstraZeneca may increase R&D investment to offset recent failures and accelerate new drug development. A budget increase would signal management’s commitment to long-term growth.
earnings prediction market
- Implied probability (Yes)
- 75%
- Closes
- 2027-03-31
About this prediction
Resolution criteria
AstraZeneca’s reported R&D expenses for the full fiscal year 2026 exceed the 2025 R&D expenses by at least 5% when reported in its 2026 annual or Q4 2026 earnings filings (or equivalent regulatory disclosures).
Source: user-generated
More earnings markets
- Will cash burn exceed $5M in Q4? — 65% Yes
- Will Venyra beat Q4 2026 revenue consensus of $230M? — 85% Yes
- Will Nuburu secure emergency financing by Q3 end? — 35% Yes
- Will Everpure, Inc. report a non-GAAP EPS beat for the quarter ended June 30, 2026? — 50% Yes
- Will KR miss Q4 operating margin guidance? — 65% Yes
- Will George Risk report Q4 2026 revenue above $13M? — 85% Yes
- Will DCI beat Q4 EPS consensus of $0.88? — 65% Yes
- Will inventory days decrease below 70 by year-end? — 40% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…